INKT Company Profile and Key Details

MiNK Therapeutics, Inc. (NASDAQ:INKT) closed at $10.45 USD, gaining $0.17 (1.65%) from the previous close of $10.28. The stock is currently mid-range between its 52-week high and low $6.34 and $76.00. With a market capitalization of about $49.05 million, MiNK Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.35). Key stats such as the average daily volume over the past year has been around 11.16 thousand shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, MiNK Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jennifer S. Buell, the company employs approximately 23 people and listed since October 15, 2021. MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.

INKT has shown mixed momentum, losing -1.5% over the past week and -15.57% over the past quarter, though year-to-date performance is up 6.01%. Short-term trend indicators are bullishly aligned (SMA20 -2.22%, SMA50 -5.85%, SMA200 -13.33%). The stock’s 14-day RSI is 41.91 (neutral), while the ATR of 0.43 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -85.49% below its high and over 73.97% above its low. Average 10-day trading volume of 5.96 thousand shares is below the 3-month average of 11.46 thousand, indicating normal recent market interest.

MiNK Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.09. This means the shares are trading below this model’s fair value.

MiNK Therapeutics, Inc. generated EPS of -$3.03 over the past year. Five-year average earnings growth is 16.86%. Wall Street analysts project EPS growth of -10.42% annually over the next five years. The latest quarter delivered EPS of -$649.95. The next quarter is forecast at -$0.68. Next year's EPS is expected at $4.76. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $35.00. The high target offers 234.93% upside. The low target suggests 234.93% downside. The mean target is $35.00. This offers 234.93% upside. MiNK Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 75475.09%. The prior quarter beat by 92.73%. Over the last six quarters, Apple has recorded several small beats. These include -30.0% in August 13, 2024.

MiNK Therapeutics, Inc. has 3.99 million shares outstanding. The public float is 1.55 million shares, elevated short interest at 3.43% of float. This equals 35.42 thousand shares. The short ratio is 0.01 days. Institutional investors hold 3.99% of the float. Insiders own 65.69%. AGENUS INC holds 21.77 million shares, ARMEN GARO H has 1.87 million shares and WIINBERG ULF has 281.64 thousand shares. Over the past six months, insider transactions show net selling. They sold 500.00 shares across 2 transactions.

MiNK Therapeutics, Inc. trades at a P/E ratio of -3.71, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -3.39 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.04, also below market averages.

Our AI price prediction model suggests that MiNK Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.4%, with price expected at $9.99 by March 23, 2026, within a range of $9.48 to $10.50 3-Month Outlook: Projected fall of -83.92%, reaching $1.68 by June 05, 2026, with a range of $0.28 to $2.44. 1-Year Outlook: Projected gain of 16.65%, with price at $12.19 by March 09, 2027, within a range of $4.57 to $12.34.

MiNK Therapeutics, Inc. (NASDAQ:INKT) shares are flat 6.01% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows MiNK Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.71. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.46, suggesting 57.51% upside. Our AI forecast model points to short-term weakness (-4.4% over two weeks), a medium-term fall (-83.92% over three months), and a longer-term gain (16.65% over one year), with expected trading ranges indicating moderate volatility.